Compare EVTC & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVTC | COLL |
|---|---|---|
| Founded | 1988 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.5B |
| IPO Year | 2013 | 2015 |
| Metric | EVTC | COLL |
|---|---|---|
| Price | $30.20 | $46.06 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | $35.80 | ★ $51.17 |
| AVG Volume (30 Days) | 379.5K | ★ 514.4K |
| Earning Date | 02-25-2026 | 02-26-2026 |
| Dividend Yield | ★ 0.67% | N/A |
| EPS Growth | ★ 76.90 | N/A |
| EPS | ★ 2.26 | 1.63 |
| Revenue | ★ $903,381,000.00 | $757,067,000.00 |
| Revenue This Year | $11.45 | $26.17 |
| Revenue Next Year | $5.64 | $3.65 |
| P/E Ratio | ★ $13.26 | $28.25 |
| Revenue Growth | 9.67 | ★ 26.34 |
| 52 Week Low | $26.72 | $23.23 |
| 52 Week High | $38.56 | $50.79 |
| Indicator | EVTC | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 55.16 | 48.05 |
| Support Level | $28.65 | $43.62 |
| Resistance Level | $30.28 | $46.94 |
| Average True Range (ATR) | 0.77 | 1.84 |
| MACD | -0.02 | -0.19 |
| Stochastic Oscillator | 77.04 | 50.16 |
Evertec Inc is a transaction processing business in Latin America and the Caribbean. Its business segments are Merchant Acquiring, Payment Services - Puerto Rico & Caribbean, Latin America Payments and Solutions, and Business Solutions which derive maximum revenue. The company serves a diversified customer base of financial institutions, merchants, corporations, and government agencies with mission-critical technology solutions that enable them to issue, process, and accept transactions securely. It derives maximum revenue from Latin America Payments and Solutions. Geographically, it operates in Puerto Rico, Caribbean, and Latin America.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.